In the recently announced 2025 TITAN Health Awards, Che-Wei Chang, an outstanding talent in the field of clinical medicine, received the Gold Winner Award in the “Outstanding Healthcare Achievements – Outstanding Oncology Specialist” category. This prestigious international accolade marks the growing impact of medical expertise from Asia on the global stage of cancer diagnosis and treatment.
As one of the most prestigious honors in healthcare, the TITAN Health Awards recognize those who have achieved the highest level of excellence across all sectors of the medical and healthcare industry. The Outstanding Oncology Specialist category, in which Che-Wei Chang was honored, specifically recognizes professionals who have made groundbreaking contributions to oncology research and practice. The selection process for this award is known for its rigor, assessing not only clinical expertise but also innovation, impact, and leadership in advancing cancer care.
Its evaluation criteria span multiple aspects, including breakthrough achievements in clinical practice, scientific research innovation, measurable improvements in patient outcomes, and overall industry influence. The judging panel, composed of international medical experts, ensures that the process remains both professional and impartial. This year’s judging panel included authoritative experts like Dr. Viswakanth Makutam, who brings years of specialized experience in oncology clinical trials, including research into patient diversity challenges in hematologic malignancies, enhancing the credibility and authority of the award selection process.
One of the key factors that impressed the jury was Che-Wei Chang’s sustained contributions to medical communication and academic exchange on the global stage. His thought leadership in gynecologic oncology has been repeatedly showcased through invited talks at the Asian Society of Gynecologic Oncology (ASGO).
At the ASGO 2024 Conference held in Bali, Indonesia, themed “Close the Gap in Gynecologic Cancer Care in Asia”, Che-Wei Chang presented a detailed case discussion of a 66-year-old patient with high-grade serous carcinoma of the uterus, treated at Taipei Veterans General Hospital. He shared an in-depth overview of the patient’s full treatment journey, from diagnosis and surgery to multiple lines of chemotherapy, targeted therapy, and combined immunotherapy. Integrating the NCCN (National Comprehensive Cancer Network) Guidelines, he highlighted the strategic timing and challenges of using immune checkpoint inhibitors in recurrent cases, providing highly practical insights that bridged evidence-based medicine and personalized care.
This impact continued at the joint ASGO 2025 conference this July in Tokyo. Che-Wei Chang was again invited as a speaker, this time focusing on a cervical cancer case. His presentation resonated deeply with the conference theme, “New Perspectives of Gynecologic Oncology: Care Beyond Cure“. Detailing the case of a patient with locally advanced cervical cancer, he elaborated on a comprehensive treatment strategy centered around immunotherapy. This included the integration of concurrent chemoradiation, precision typing based on PD-L1 expression, long-term maintenance therapy management, and an exploratory shift to Durvalumab following the development of resistance. His report, supported by the latest clinical data from trials like KEYNOTE-A18 and vividly illustrated with serial imaging findings, powerfully articulated a philosophy of whole-lifecycle patient care. The content holds significant practical value for advancing standardized cervical cancer treatment protocols across Asia.
Beyond academic exchange, it is his frontline clinical breakthroughs that formed the cornerstone of his recognition. Having dedicated years to gynecologic oncology, he has driven innovation in overcoming drug resistance and refining precision treatment systems for recurrent ovarian and cervical cancers, bringing renewed hope to patients worldwide. His original research has not only influenced international clinical guidelines but also helped disseminate next-generation diagnostic and therapeutic protocols. Through his leadership, professional knowledge has been effectively transformed into scalable clinical pathways and industry standards, amplifying his impact across the field.
Looking ahead, Che-Wei Chang remains committed to exploring the mechanisms of drug resistance in gynecologic cancers, translating more laboratory discoveries into real-world clinical benefits, and contributing to the vision of a “Healthy China”. Industry experts view his award as both a recognition of personal excellence and a milestone signifying that Asia’s gynecologic oncology practices are now reaching the forefront of global medicine with Che-Wei Chang standing as one of the driving forces behind that progress.
